ストックスクリーナーアプリを入手
36.32
0.47%
-0.17
アフターアワーズ：
36.20
-0.12
-0.33%
前日終値:
$36.49
開ける：
$36.49
24時間の取引高:
1.45M
Relative Volume:
0.68
時価総額：
$5.90B
収益：
-
当期純損益:
$-328.94M
株価収益率:
-14.83
EPS:
-2.4483
ネットキャッシュフロー:
$-266.00M
1週間 パフォーマンス:
-1.71%
1か月 パフォーマンス:
+6.82%
6か月 パフォーマンス:
+119.19%
1年 パフォーマンス:
+645.79%
1日の値動き範囲:
$35.69
$36.92
1週間の範囲:
$35.69
$37.58
52週間の値動き範囲:
$4.115
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.32 | 5.92B | 0 | -328.94M | -266.00M | -2.4483 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2025-11-10 | アップグレード | Stifel | Hold → Buy |
| 2025-11-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stock - MSN
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
Precision Trading with Cogent Biosciences Inc. (COGT) Risk Zones - Stock Traders Daily
Revenue Check: What is the long term forecast for Cogent Biosciences Inc stockSell Signal & Reliable Entry Point Alerts - baoquankhu1.vn
Does Bezuclastinib’s Real-Time FDA Review and NDA Filing Change The Bull Case For Cogent Biosciences (COGT)? - Yahoo Finance
COGT (Cogent Biosciences) PE Ratio : At Loss (As of Apr. 11, 2026) - GuruFocus
Cogent Biosciences (COGT) Is Up 6.1% After FDA NDA Filing For Bezuclastinib In GIST - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller Admires Upside Potential of This Stock - Insider Monkey
Gainers Report: What is the long term forecast for Cogent Biosciences Inc stock2026 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn
A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA - Sahm
COGT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Cogent Biosciences Inc To Discuss Full SUMMIT Data at ASH Transcript - GuruFocus
[Form 4] Cogent Biosciences, Inc. Insider Trading Activity - Stock Titan
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail
Technical Reactions to COGT Trends in Macro Strategies - Stock Traders Daily
Cogent Biosciences, Inc.Common Stock (NQ: COGT - The Chronicle-Journal
Cogent Biosciences, Inc. (COGT) stock price, news, quote and history - Yahoo Finance UK
Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT) - Seeking Alpha
Dip Buying: What are analysts price targets for Cogent Biosciences Inc2026 Top Decliners & Risk Controlled Daily Trade Plans - baoquankhu1.vn
COGT Stock Chart | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GISTHas The Bull Case Changed? - Sahm
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) - Sahm
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - Investing News Network
Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2%Should You Sell? - MarketBeat
Biotech Stocks To ConsiderApril 1st - MarketBeat
Cogent Biosciences (COGT) Advances Bezuclastinib Application - GuruFocus
Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors in US - marketscreener.com
Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - marketscreener.com
Fairmount funds sells Cogent Biosciences (COGT) shares for $242.6m By Investing.com - Investing.com Canada
Form 144 | Cogent Biosciences(COGT.US) Director Proposes to Sell 242.62 Million in Common Stocks - Moomoo
COGT (NASDAQ) Form 144 shows proposed 7.0M share sale after conversion - Stock Titan
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts - Proactive financial news
Hennion & Walsh Asset Management Inc. Buys 37,938 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - AOL.com
Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
Assenagon Asset Management S.A. Trims Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers - TipRanks
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - AOL.com
Vanguard disaggregates holdings; Cogent Biosciences (COGT) shows 0% ownership - Stock Titan
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - AOL.com
Aug Analyst Calls: Is Cogent Biosciences Inc forming a double bottomPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest - Sahm
Why Cogent Biosciences Stock Is Surging Higher Now - TipRanks
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions - Yahoo Finance
Trading the Move, Not the Narrative: (COGT) Edition - Stock Traders Daily
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):